ישראל - עברית - Ministry of Health

rafa laboratories ltd - mesalazine - פתילות - mesalazine 1000 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.

ישראל - עברית - Ministry of Health

sam-on ltd - nicotinic acid; pepsin; sodium glycerophosphate - טיפות - pepsin 0.6 %w/v; nicotinic acid 0.2 %w/v; sodium glycerophosphate 0.8 %w/v - pepsin and acid preparations - pepsin and acid preparations - treatment of constipation and flatulence.

ישראל - עברית - Ministry of Health

gramse intrnational natural products limited partnership, israel - acetylsalicylic acid - טבליה - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - for inhibition of platelet aggregation

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

ישראל - עברית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 2000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

ישראל - עברית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 4000 iu / 0.4 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

ישראל - עברית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 10000 iu/ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat